Skip to main content

Pletal Side Effects

Generic name: cilostazol

Medically reviewed by Drugs.com. Last updated on Feb 5, 2024.

Note: This document contains side effect information about cilostazol. Some dosage forms listed on this page may not apply to the brand name Pletal.

Applies to cilostazol: oral tablet.

Warning

Oral route (Tablet)

Cilostazol is contraindicated in congestive heart failure of any severity. Cilostazol and many of its metabolites inhibit phosphodiesterase III. Several drugs with this pharmacologic effect have resulted in decreased survival compared with placebo in patients with class III to IV congestive heart failure.

Serious side effects of Pletal

Along with its needed effects, cilostazol (the active ingredient contained in Pletal) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking cilostazol:

More common

Less common

Incidence not known

Get emergency help immediately if any of the following symptoms of overdose occur while taking cilostazol:

Symptoms of overdose

Other side effects of Pletal

Some side effects of cilostazol may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

Incidence not known

For Healthcare Professionals

Applies to cilostazol: oral tablet.

General

The most frequent adverse reactions resulting in discontinuation of therapy were headache, palpitation, and diarrhea.[Ref]

Nervous system

Very common (10% or more): Headache (up to 34%), dizziness (up to 10%)

Frequency not reported: Tinnitus

Postmarketing reports: Intracranial hemorrhage, cerebral hemorrhage, cerebrovascular accident, extradural hematoma, subdural hematoma

Gastrointestinal

Very common (10% or more): Diarrhea (up to 19%), abnormal stools (up to 15%)

Common (1% to 10%): Dyspepsia, abdominal pain

Frequency not reported: Melena

Postmarketing reports: Gastrointestinal hemorrhage, vomiting, flatulence, nausea[Ref]

Immunologic

Very common (10% or more): Infection (up to 14%)

Postmarketing reports: Anaphylaxis, angioedema, hypersensitivity[Ref]

Respiratory

Very common (10% or more): Rhinitis (up to 12%), pharyngitis (up to 10%)

Frequency not reported: Epistaxis

Postmarketing reports: Pulmonary hemorrhage, interstitial pneumonia[Ref]

Cardiovascular

Very common (10% or more): Palpitation (up to 10%)

Common (1% to 10%): Tachycardia

Frequency not reported: Atrial fibrillation, heart failure, myocardial infarction, nodal arrhythmia, supraventricular tachycardia, ventricular extrasystoles, ventricular tachycardia, left ventricular outflow obstruction

Postmarketing reports: Torsade de pointes, QTc prolongation, angina pectoris, hot flushes, blood pressure increased, subacute stent thrombosis, hypertension[Ref]

Other

Common (1% to 10%): Peripheral edema

Frequency not reported: Fever, generalized edema, malaise

Postmarketing reports: Pain, chest pain[Ref]

Metabolic

Frequency not reported: Anorexia, hyperuricemia

Postmarketing reports: Blood glucose increased, blood uric acid increased[Ref]

Ocular

Frequency not reported: Conjunctivitis, retinal hemorrhage[Ref]

Dermatologic

Frequency not reported: Urticaria

Postmarketing reports: Subcutaneous hemorrhage, pruritus, skin eruptions, Stevens-Johnson syndrome, skin drug eruption, rash[Ref]

Hematologic

Frequency not reported: Anemia

Postmarketing reports: Aplastic anemia, granulocytopenia, pancytopenia, bleeding tendency[Ref]

Genitourinary

Frequency not reported: Urinary frequency

Postmarketing reports: Hematuria[Ref]

Renal

Frequency not reported: Creatinine increased

Postmarketing reports: BUN increased[Ref]

Psychiatric

Frequency not reported: Insomnia[Ref]

Hepatic

Postmarketing reports: Hepatic dysfunction, abnormal liver function tests, jaundice[Ref]

References

1. Product Information. Pletal (cilostazol). Otsuka American Pharmaceuticals Inc. 2001;PROD.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.